Background: Biomarker-driven molecular imaging has emerged as an integral part of cancer
precision radiotherapy. The use of molecular imaging probes, including nanoprobes, have …

Assessing the efficacy of cancer therapeutics in mouse models is a critical step in treatment
development. However, low-resolution measurement tools and small sample sizes make …

The availability of high-fidelity animal models for oncology research has grown enormously
in recent years, enabling preclinical studies relevant to prevention, diagnosis, and treatment …

In anticancer research, tumor growth measured in mouse models is important for assessing
treatment efficacy for a treatment to progress to human clinical trials. Statistical analysis of …

Patient-derived xenografts (PDXs) are generated by engrafting human tumours into mice.
Serially transplantable PDXs are used to study tumour biology and test therapeutics, linking …

Although patient-derived xenografts (PDX) are commonly used for preclinical modeling in
cancer research, a standard approach to in vivo tumor growth analysis and assessment of …

Cancer cells exhibit rewired transcriptional regulatory networks that promote tumor growth
and survival. However, the mechanisms underlying the formation of these pathological …

In the last decade, organoid research has entered a golden era, signifying a pivotal shift in
the biomedical landscape. The year 2023 marked a milestone with the publication of …

Oncology drug efficacy is evaluated in mouse models by continuously monitoring tumor
volumes, which can be mathematically described by growth kinetic models. Although past …

Overexpression of the human epidermal growth receptor 1 (HER1, EGFR) and 2 (HER2) are
common in breast cancer (BC) and confer a poor prognosis. HER2-targeted pertuzumab …